Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 intratumoral Fibromun + Darleukin in locally advanced cutaneous squamous cell carcinoma after intolerance or progression on systemic therapy
2025-523231-19-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- Apr 2026
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of onfekafusp alfa and darleukin in cutaneous squamous cell carcinoma (cSCC), sponsored by Philogen. Primary endpoint: Best Overall Response Rate. Planned start Apr 2026; status: authorised.
02
Drugs
onfekafusp alfadarleukin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2025-523231-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523231-19-00.